Acute pain

Pennsylvania Pain and Spine Institute Welcomes New Physician

Retrieved on: 
Tuesday, July 20, 2021
Acute pain, Pain management, Palliative care

In an effort to provide patients within the region, and beyond, with increased care options and appointment opportunities, Dr. Ali Shah, MD joins Pennsylvania Pain and Spine Institute (PA Pain & Spine) to see patients beginning in August 2021.

Key Points: 
  • In an effort to provide patients within the region, and beyond, with increased care options and appointment opportunities, Dr. Ali Shah, MD joins Pennsylvania Pain and Spine Institute (PA Pain & Spine) to see patients beginning in August 2021.
  • PA Pain & Spine is a rapidly growing pain medicine and rehabilitation practice treating upwards of 500 patients per week with various conditions.
  • Pennsylvania Pain and Spine Institute was founded in 2013 by Ivy League trained physicians Dr. David Qu, MD and Dr. Robert Kelly, DO.
  • The practice currently has two offices located in Chalfont, Pennsylvania and Quakertown, Pennsylvania and treats patients with any type of pain.

MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns

Retrieved on: 
Tuesday, July 20, 2021
Acute pain, Burn, Heat transfer, Bromelain, Health, Clinical medicine, Medicine

"It is gratifying to know that NexoBrid, with these highly compelling top-line results, is one step closer to becoming available as a treatment option for pediatric patients with severe burns."

Key Points: 
  • "It is gratifying to know that NexoBrid, with these highly compelling top-line results, is one step closer to becoming available as a treatment option for pediatric patients with severe burns."
  • The current mode of pediatric burn management requires intensive medical therapy, which poses challenges due to the surgical complexities in treating young patients with severe burns.
  • Having NexoBrid as a non-surgical option provides a minimally invasive alternative to the current surgical standard of care for treating severe burns in pediatric patients.
  • The NexoBrid CIDS study is a multicenter, multinational, randomized, controlled, open label study, performed in children with deep partial thickness (DPT) and full thickness (FT) thermal burns.

Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain

Retrieved on: 
Monday, July 19, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Nervous system, Pain, Acute pain, Nociception, Neuropathic pain, Peripheral neuropathy, Transcutaneous electrical nerve stimulation, Nav1.8

The Phase 2 studies are randomized, double-blind, placebo-controlled trials that will evaluate multiple doses of VX-548 in patients with acute pain following bunionectomy surgery or abdominoplasty surgery.

Key Points: 
  • The Phase 2 studies are randomized, double-blind, placebo-controlled trials that will evaluate multiple doses of VX-548 in patients with acute pain following bunionectomy surgery or abdominoplasty surgery.
  • The primary endpoint in both studies is the time-weighted Sum of the Pain Intensity Difference over the first 48 hours of treatment (SPID48).
  • NaV1.8 is a genetically validated novel target for the treatment of pain, and Vertex has previously demonstrated clinical proof-of-concept with a small molecule investigational treatment targeting NaV1.8 in multiple pain indications including acute pain, neuropathic pain and musculoskeletal pain.
  • Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

electroCore announces Dr. Peter Staats to receive Lifetime Achievement Award from the American Society of Pain and Neuroscience

Retrieved on: 
Monday, July 19, 2021
Branches of biology, Nervous system, Medicine, Acute pain, Peter Staats, Pain management, Neurotechnology, North American Neuromodulation Society, American Society of Interventional Pain Physicians, Neuromodulation, Pain Physician, Pain

ROCKAWAY, NJ, July 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its cofounder and Chief Medical Officer, Dr. Peter Staats, is to receive a Lifetime Achievement Award at the American Society of Pain and Neuroscience Annual Conference on July 24th, 2021.

Key Points: 
  • ROCKAWAY, NJ, July 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its cofounder and Chief Medical Officer, Dr. Peter Staats, is to receive a Lifetime Achievement Award at the American Society of Pain and Neuroscience Annual Conference on July 24th, 2021.
  • Dr. Staats will be honored for his lifelong contribution to field of pain and neuromodulation, advancing the relief from pain through science, clinical education, and research.
  • Dr. Staats has written or co-edited 13 books and over 450 articles, abstracts, monographs, and book chapters on pain medicine in publications that include the Journal of the American Medicine Association, Pain, Anesthesiology, Lancet Neurology and the Journal of Clinical Oncology.
  • Dr. Staats is the former President of the North American Neuromodulation Society, American Society of Interventional Pain Physicians, New Jersey Society of Interventional Pain Physicians, and the Southern Pain Society.

Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN)

Retrieved on: 
Monday, July 19, 2021
Branches of biology, Neuroscience, Neurotechnology, Neurophysiology, Pain, Acute pain, Sensory systems, Neuromodulation, Spinal cord stimulator, Peripheral neuropathy, Spinal cord, Neurostimulation

This approval is specific to Nevro's unique 10 kHz stimulation, and Nevro now has the only spinal cord stimulation system approved by the FDA with a specific indication to treat PDN.

Key Points: 
  • This approval is specific to Nevro's unique 10 kHz stimulation, and Nevro now has the only spinal cord stimulation system approved by the FDA with a specific indication to treat PDN.
  • Study participants demonstrated significantly improved and sustained outcomes with 10 kHz Spinal Cord Stimulation (SCS), including substantial, sustained pain relief and improved health-related quality of life.
  • Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain.
  • Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: ARandomized Clinical Trial.JAMA Neurol.2021 Jun 1;78(6):687-698. doi:10.1001/jamaneurol.2021.0538.

Swift Medical Raises $35 Million Series B to Transform Wound Care Delivery with AI

Retrieved on: 
Thursday, July 15, 2021
Technology, Mobile, Wireless, Nursing, Hospitals, Software, Other Health, Managed care, Health, Data management, Clinical medicine, Medicine, First aid, Injuries, Medical emergencies, Acute pain, Wound, Health sciences

Swift Medical, the global leader in digital wound care, announced today a Series B funding round of $35 million USD.

Key Points: 
  • Swift Medical, the global leader in digital wound care, announced today a Series B funding round of $35 million USD.
  • This latest round of funding will help Swift Medical expand their leading market position and scale their digital wound management platform across the care continuum in North America.
  • With this investment, Swift Medical will be able to advance and accelerate its mission to transform the future of wound care: to prevent wounds before they even happen and improve quality of care for every patient with a wound.
  • Swift Medical is rapidly growing their team to take on the wound care epidemic.

Nalu Medical Announces Scientific Presentations at 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting

Retrieved on: 
Thursday, July 15, 2021
Branches of biology, Nervous system, Medicine, Pain, Neurotechnology, Acute pain, Nociception, Neuromodulation, Neurostimulation, Nalu, Neuropathic pain, Pain management

CARLSBAD, Calif., July 15, 2021 /PRNewswire-PRWeb/ --Nalu Medical, Inc. ("Nalu"), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announced that the scientific presentation schedule during the 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting in Orlando, Florida will include three abstract submissions all selected for oral presentations.

Key Points: 
  • CARLSBAD, Calif., July 15, 2021 /PRNewswire-PRWeb/ --Nalu Medical, Inc. ("Nalu"), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announced that the scientific presentation schedule during the 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting in Orlando, Florida will include three abstract submissions all selected for oral presentations.
  • We are a medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain.
  • Our Nalu Neurostimulation System, or Nalu System, delivers gentle electrical pulses to the nervous system to modulate pain signals to the brain.
  • Nalu, the Nalu logo and nPower are trademarks of Nalu Medical, Inc.
    1.

Dr. Robert Moghim to Participate in Clinical Trial for Knee Pain Using Freedom Peripheral Nerve Stimulator

Retrieved on: 
Thursday, July 15, 2021
Branches of biology, Medicine, Clinical medicine, Neurotechnology, Skeletal disorders, Pain, Acute pain, Neuromodulation, Neurophysiology, Stimulator, Osteoarthritis, Arthritis

DENVER, July 15, 2021 /PRNewswire/ --Dr. Robert Moghim at Colorado Pain Care has recently been approved to participate in a clinical trial on Peripheral Nerve Stimulation for Knee Pain.

Key Points: 
  • DENVER, July 15, 2021 /PRNewswire/ --Dr. Robert Moghim at Colorado Pain Care has recently been approved to participate in a clinical trial on Peripheral Nerve Stimulation for Knee Pain.
  • This study is designed to assess the effectiveness of the Freedom Peripheral Nerve Stimulator (PNS) System for treating chronic knee pain caused by osteoarthritis.
  • Dr. Moghim will be enrolling 10 participants for this study that is expected to last 2 years.
  • The results are intended to help people with arthritic knee pain in the future.

2021 Report on Ocular Pain Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Pharmaceutical, Health, Optical, Pain, Nervous system, Branches of biology, Nociception, Acute pain, Suffering

The "Ocular Pain (Eye Pain) (Central Nervous System) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ocular Pain (Eye Pain) (Central Nervous System) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Ocular Pain (Eye Pain), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain (Eye Pain) and features dormant and discontinued projects.
  • The report reviews key players involved in the development of Ocular Pain (Eye Pain) (Central Nervous System) therapeutics and enlists all their major and minor projects.

CityPT Aims to Help with Chronic Pain with New Model of Physical Therapy

Retrieved on: 
Wednesday, July 14, 2021
Health sciences, Health, Manual therapy, Rehabilitation medicine, Allied health professions, Acute pain, Health policy, Therapy, Physical therapy, Pain

Shirk's own experiences with traditional physical therapy exposed numerous gaps in the system that discourage patients from healing.

Key Points: 
  • Shirk's own experiences with traditional physical therapy exposed numerous gaps in the system that discourage patients from healing.
  • "I want CityPT to provide the fastest possible way for people to get help from experts," Shirk explains.
  • Also, traditional physical therapy practices don't always address the underlying causes of pain.
  • "Physical therapy is about consulting with a musculoskeletal expert with the goal of becoming an expert on your own unique body," Shirk says.